Purple Biotech Ownership
| KTOV Stock | ILA 11.00 1.90 14.73% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Purple |
Purple Stock Ownership Analysis
The company has price-to-book ratio of 1.27. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Purple Biotech recorded a loss per share of 0.17. The entity last dividend was issued on the 30th of October 2012. The firm had 1:20 split on the 6th of January 2019. Kitov Pharma Ltd, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs. The company was formerly known as Kitov Pharmaceuticals Holdings Ltd. and changed its name to Kitov Pharma Ltd in January 2018. KITOV PHARMA operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 9 people. To find out more about Purple Biotech contact Itzhak Israel at 972 3 933 3121 or learn more at http://www.kitovpharma.com.Purple Biotech Outstanding Bonds
Purple Biotech issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Purple Biotech uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Purple bonds can be classified according to their maturity, which is the date when Purple Biotech has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Purple Stock
When determining whether Purple Biotech is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Purple Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Purple Biotech Stock. Highlighted below are key reports to facilitate an investment decision about Purple Biotech Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Purple Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Purple Stock refer to our How to Trade Purple Stock guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.